The study aims to quantify the population impact of prescribing cholinesterase inhibitors to slow the cognitive decline in Alzheimer's disease (AD), and to compare with the benefit of treating hypertension to prevent the onset of AD. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.